This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Former Senator Ben Sasse has become an unlikely public face of a drug that researchers are ...

When former Nebraska Sen. Ben Sasse was diagnosed with Stage 4 pancreatic cancer in December, he was given three to four months to live. Now a drug by Revolution Medicines is giving him precious more ...

Revolution Medicines said its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% ...

New clinical trial data show KRAS-blocking drugs may significantly improve survival for the disease. “I think this is truly an earth-shattering moment in pancreatic cancer.” Daraxonrasib, an ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

A glimmer of hope may be on the horizon for a ruthless cancer that former Sen. Ben Sasse (R-Neb.) once called a “definite death sentence.” An experimental treatment from Revolution Medicines helped ...

A new drug is offering hope and time for patients and their families and doubling the survival rate for one of the most deadly cancers. Donna Husar is grateful for the extra time. In 2020, her husband ...

Please provide your email address to receive an email when new articles are posted on . Daraxonrasib nearly doubled survival vs. chemotherapy for pretreated patients with metastatic pancreatic cancer.

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

A randomized, phase 2 clinical trial shows that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from ...